Provided herein in aspects is an antibacterial combination comprising a thiopeptide antibiotic and an iron inhibitor. Methods of treatment and/or prevention of bacterial infections using the combination are also provided as well as methods of sensitizing a gram-negative bacteria to a thiopeptide antibiotic and methods of screening a molecule for antimicrobial activity.

Provided herein in aspects is an antibacterial combination comprising a thiopeptide antibiotic and an iron inhibitor. Methods of treatment and/or prevention of bacterial infections using the combination are also provided as well as methods of sensitizing a gram-negative bacteria to a thiopeptide antibiotic and methods of screening a molecule for antimicrobial activity.

Provided herein in aspects is an antibacterial combination comprising a thiopeptide antibiotic and an iron inhibitor. Methods of treatment and/or prevention of bacterial infections using the combination are also provided as well as methods of sensitizing a gram-negative bacteria to a thiopeptide antibiotic and methods of screening a molecule for antimicrobial activity.

There is provided an antitumour cell, liposome or micelle, comprising at least one charge-modified globin associated with the membrane of the cell, liposome or micelle, and methods of making and using the same.

Pharmaceutical formulations to prevent or treat hemorrhagic shock are provided. The pharmaceutical formulations comprise an oxygenation complement comprising a hemoglobin-based oxygen carried (HBOC) and blood plasma. Related methods to prepare the pharmaceutical preparations are also provided. Furthermore, methods to prevent or treat hemorrhagic shock are provided.

Pharmaceutical formulations to prevent or treat hemorrhagic shock are provided. The pharmaceutical formulations comprise an oxygenation complement comprising a hemoglobin-based oxygen carried (HBOC) and blood plasma. Related methods to prepare the pharmaceutical preparations are also provided. Furthermore, methods to prevent or treat hemorrhagic shock are provided.

Pharmaceutical formulations to prevent or treat hemorrhagic shock are provided. The pharmaceutical formulations comprise an oxygenation complement comprising a hemoglobin-based oxygen carried (HBOC) and blood plasma. Related methods to prepare the pharmaceutical preparations are also provided. Furthermore, methods to prevent or treat hemorrhagic shock are provided.

Oxygenation constituents and finished oxygenation media, as well as methods of making oxygenation constituents and finished oxygenation media are provided. The oxygenation constituents comprise a hemoglobin preparation, and a red blood cell preparation. The oxygenation constituents comprise from about 10% to about 99% by weight hemoglobin of the hemoglobin preparation and the balance by weight hemoglobin of the oxygenation constituents comprise a red blood cell preparation. The finished oxygenation media comprise the oxygenation constituents and one or more other ingredients such as a diluent, or excipient. The finished oxygenation media can be used to ex-vivo preserve organs or tissue.

Oxygenation constituents and finished oxygenation media, as well as methods of making oxygenation constituents and finished oxygenation media are provided. The oxygenation constituents comprise a hemoglobin preparation, and a red blood cell preparation. The oxygenation constituents comprise from about 10% to about 99% by weight hemoglobin of the hemoglobin preparation and the balance by weight hemoglobin of the oxygenation constituents comprise a red blood cell preparation. The finished oxygenation media comprise the oxygenation constituents and one or more other ingredients such as a diluent, or excipient. The finished oxygenation media can be used to ex-vivo preserve organs or tissue.

Described are silk fibroin nanoparticles encapsulating oxygen carriers and compositions containing silk fibroin nanoparticles encapsulating oxygen carriers. Also described are methods of using the silk fibroin nanoparticles encapsulating oxygen carriers as artificial blood substitutes.